Dark Forest Capital Management LP Acquires Shares of 22,978 Pediatrix Medical Group, Inc. (NYSE:MD)

Dark Forest Capital Management LP bought a new position in Pediatrix Medical Group, Inc. (NYSE:MD) during the 2nd quarter, Holdings Channel reports. The institutional investor bought 22,978 shares of the company’s stock, valued at approximately $173,000.

A number of other institutional investors have also recently modified their holdings of the stock. AXA S.A. boosted its stake in Pediatrix Medical Group by 6.2% in the 2nd quarter. AXA S.A. now owns 165,264 shares of the company’s stock worth $1,248,000 after purchasing an additional 9,664 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of Pediatrix Medical Group in the second quarter worth approximately $214,000. Cubist Systematic Strategies LLC grew its holdings in shares of Pediatrix Medical Group by 639.4% during the second quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company’s stock valued at $2,192,000 after buying an additional 251,072 shares during the last quarter. Aristeia Capital L.L.C. bought a new stake in shares of Pediatrix Medical Group during the second quarter valued at approximately $687,000. Finally, Marshall Wace LLP lifted its position in Pediatrix Medical Group by 162.6% in the 2nd quarter. Marshall Wace LLP now owns 134,191 shares of the company’s stock valued at $1,013,000 after acquiring an additional 83,082 shares in the last quarter. 97.71% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Pediatrix Medical Group

In related news, CFO C Marc Richards sold 32,562 shares of Pediatrix Medical Group stock in a transaction on Friday, August 9th. The stock was sold at an average price of $10.08, for a total transaction of $328,224.96. Following the transaction, the chief financial officer now directly owns 192,785 shares in the company, valued at $1,943,272.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Laura A. Linynsky sold 7,000 shares of the stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total value of $78,120.00. Following the completion of the sale, the director now directly owns 30,805 shares of the company’s stock, valued at $343,783.80. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO C Marc Richards sold 32,562 shares of Pediatrix Medical Group stock in a transaction on Friday, August 9th. The shares were sold at an average price of $10.08, for a total transaction of $328,224.96. Following the transaction, the chief financial officer now owns 192,785 shares in the company, valued at approximately $1,943,272.80. The disclosure for this sale can be found here. Insiders sold 68,100 shares of company stock worth $701,889 in the last three months. Corporate insiders own 2.00% of the company’s stock.

Wall Street Analyst Weigh In

MD has been the subject of a number of research analyst reports. Jefferies Financial Group raised Pediatrix Medical Group from a “hold” rating to a “buy” rating and lifted their target price for the stock from $8.00 to $14.00 in a report on Thursday, September 26th. Truist Financial boosted their target price on Pediatrix Medical Group from $8.00 to $10.00 and gave the stock a “hold” rating in a research report on Thursday, August 15th. Deutsche Bank Aktiengesellschaft raised shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating and set a $8.00 price target on the stock in a report on Friday, June 7th. UBS Group boosted their price objective on shares of Pediatrix Medical Group from $9.00 to $10.50 and gave the company a “neutral” rating in a report on Friday, August 9th. Finally, StockNews.com upgraded shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating in a report on Wednesday, August 7th. Five investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.30.

Pediatrix Medical Group Price Performance

NYSE MD opened at $11.60 on Tuesday. The company has a 50-day moving average price of $10.12 and a 200-day moving average price of $8.90. Pediatrix Medical Group, Inc. has a 52 week low of $6.62 and a 52 week high of $13.01. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.87. The firm has a market capitalization of $976.11 million, a P/E ratio of -13.65, a PEG ratio of 1.64 and a beta of 1.56.

Pediatrix Medical Group (NYSE:MD) last announced its earnings results on Tuesday, August 6th. The company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.03. The business had revenue of $504.30 million during the quarter, compared to analysts’ expectations of $505.49 million. Pediatrix Medical Group had a negative net margin of 12.58% and a positive return on equity of 10.59%. The firm’s revenue was up .7% on a year-over-year basis. During the same period in the prior year, the company earned $0.37 earnings per share. Equities research analysts anticipate that Pediatrix Medical Group, Inc. will post 1.19 earnings per share for the current year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.